___

[1] Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015; 152: 63-82.

[2] Danhier F, Messaoudi K, Lemaire L, Benoit J-P, Lagarce F. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. Int J Pharm. 2015; 481(1–2): 154–161.

[3] Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem cells. Neurochem Int. 2014; 77: 68–77.

[4] Wang G, Wang JJ, Tang HM, To SST. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Arch Biochem Biophys. 2015; 580: 64–74.

[5] Kuşçu L, Sezer AD. Gen Tedavisi İçin Tasarlanan ve Patent Başvurusu Yapılan Farmasötiklerin İncelenmesi ve Değerlendirilmesi. Marmara Pharm J. 2016; 20(2): 52-63.

[6] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9): 1257–1272.

[7] Yang S, Zheng Y, Chen J, Zhang Q, Zhao D, Han D, Chen X. Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. Coll Surf B. 2013; 101: 6–13.

[8] Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 2013; 21(4): 379–385.

[9] Büyükköroğlu G, Şenel B, Başaran E, Yenilmez E, Yazan Y. Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer. Eur J Pharm Biopharm. 2016; 109: 174–183. .

[10] Jin SE, Kim CK. Charge-mediated topical delivery of plasmid DNA with cationic lipid nanoparticles to the skin. Coll Surf B. 2014; 116: 582–590.

[11] Kotmakçı M, Akbaba H, Erel G, Ertan G, Kantarcı G. Improved Method for Solid Lipid Nanoparticle Preparation Based on Hot Microemulsions: Preparation, Characterization, Cytotoxicity, and Hemocompatibility Evaluation. AAPS PharmSciTech. 2017; 18(4): 1355-1365.

[12] Resnier P, David S, Lautram N, Delcroix GJR, Clavreul A, Benoit JP. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. Int J Pharm. 2013; 454(2): 748–755.

[13] Van Woensel M, Wauthoz N, Rosière R, Mathieu V, Kiss R, Lefranc F. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release. 2016; 227: 71–81.

[14] Kotmakçı M, Çetintaş VB, Kantarcı AG. Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells. Int J Pharm. 2017; 525(1): 101- 111.

[15] Kim HR, Kim IK, Bae KH, Lee SH, Lee Y, Park TG. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm. 2008; 5(4): 622–631.

[16] Gooding M, Malhotra M, McCarthy DJ, Godinho BMDC, Cryan JF, Darcy R. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: in-vitro analysis. Eur J Pharm Sci. 2015; 71: 80–92.

[17] Aral C, Akbuga J. Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA:poly(L-lysine) complexes. J Pharm Pharm Sci. 2003; 6(3): 321–326.

[18] Şalva E, Akbuğa J. The Effects to GM-CSF Expression and Fibroblast Proliferation of pGMCSF Containing Chitosan/PVP Hydrogels. Marmara Pharm J. 2016; 21(2): 228–234.

[19] Xu C, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015; 10(1): 1–12.

[20] Liu Y, An S, Li J, Kuang Y, He X, Guo Y, Ma H, Zhang Y, Ji B, Jiang C. Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer’s disease mice. Biomaterials. 2015; 80:33-45.

[21] Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1): 161–177.

[22] Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM. Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated efflux of Rhodamine 123 partially due to expression within Caco-2 cells. J Pharm Pharm Sci. 2007; 10(3): 319–331.

[23] Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012; 7: 5577–5591.

[24] Albuquerque J, Costa Moura C, Sarmento B, Reis S. Solid lipid nanoparticles: A potential multifunctional approach towards rheumatoid arthritis theranostics. Molecules. 2015; 20: 11103-11118.

[25] Messaoudi K, Saulnier P, Boesen K, Benoit JP, Lagarce F. Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide. Int J Nanomedicine. 2014; 9: 1479–1490.

[26] Yang HW, Lu YJ, Lin KJ, Hsu SC, Huang CY, She SH. EGFR conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials 2013; 34(29): 7204–7214.

[27] Chirio D, Gallarate M, Peira E, Battaglia L, Muntoni E, Riganti C. Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment. Eur J Pharm Biopharm. 2014; 88(3): 746–758.

[28] Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Curr Cancer Drug Targets. 2012; 12(3): 197–209.

[29] Erel Akbaba G, Kotmakçı M, Akbaba H, Sözer Karadağlı S, Kantarcı AG. Nanoencapsulated chitosan nanoparticles in emulsion-based oral delivery system: In vitro and in vivo evaluation of insulin loaded formulation. J Drug Deliv Sci Technol. 2016; 36:161-167.